Martin Reck

German Center for Lung Research ORCID: 0000-0002-5348-4462

4

h-index

4

Publications

12,000

Citations

Publications

4 shown

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck , R. Kaiser , Anders Mellemgaard +11 more

2014 The Lancet Oncology 923 citations

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim , Vera Hirsh , Tony Mok +15 more

2008 The Lancet 1240 citations

Frequent Co-Authors

Mark A. Socinski

Florida Hospital Cancer Institute

Robert M. Jotte

Rocky Mountain Cancer Centers

Federico Cappuzzo

Azienda Unità Sanitaria Locale Della Romagna

Francesco Orlandi

Instituto Nacional del Tórax

Daniil Stroyakovskiy

Moscow City Oncology Hospital №62

Naoyuki Nogami

Shikoku Cancer Center

Researcher Info

h-index: 4
Publications: 4
Citations: 12,000
Institution: German Center for Lung Research

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-5348-4462

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.